HYMPAVZI offers a combination of superior bleed protection compared to on-demand (OD) treatment that is well-tolerated with a straightforward, once-weekly subcutaneous injection administration that ...

The European Commission has approved Hympavzi to treat certain patients with hemophilia A or hemophilia B who have inhibitors ...

Pfizer’s Hympavzi receives European approval to treat adults and adolescents with haemophilia A or B with inhibitors: New York Thursday, May 14, 2026, 09:00 Hrs [IST] Pfizer Inc ...

Study demonstrates superiority, showing both statistically significant and clinically meaningful reduction in annualized bleeding rate with a generally well-tolerated safety profile compared to ...

An oral drug from Pfizer causes a similar amount of weight loss as the blockbuster Ozempic injection, made by rival Novo Nordisk, according to results from a phase two clinical trial. The results were ...

Pfizer (NYSE:PFE) reported Phase 2b results for its GLP-1 anti-obesity candidate, PF-08653944, showing potential for a once monthly injection. The company plans more than 20 anti-obesity trials, ...

(RTTNews) - Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, ...

The decisions by Pfizer and Merck to share their COVID-19 drug patents stands in stark contrast to the refusal of Pfizer and other vaccine-makers to release their vaccine recipes ...

Novo Nordisk has achieved tremendous success in the cardiometabolic treatment space, driven primarily by its semaglutide ...